All In Biotech

Drug Trial Radar · NCT06061536

Assess the Effectiveness and Safety of Lipovirtide Combined With Nucleoside Drugs in HIV-infected Patients.

A Randomized, Controlled, Open-label, Dose-exploration Study to Assess the Effectiveness and Safety of Lipovirtide Combined With Nucleoside Drugs in HIV-infected Patients Who Have Not Received Antiviral Treatment Before.

Last checked: Nov 20, 2026Latest source record: May 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

64

Actual

Start

Nov 2, 2023

Primary completion

Nov 29, 2024

Study completion Jan 24, 2025

Sponsor

Sponsor type
Industry
Collaborators
Institute of Pathogen Biology, Beijing, China
First posted
Sep 29, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A randomized, controlled, open-label, dose-exploration study to assess the effectiveness and safety of Lipovirtide combined with nucleoside drugs in HIV-infected patients who have not received antiviral treatment before.

Conditions

  • HIV

Interventions

  • Lipovirtide 10mgDrug

    Lipovirtide 10mg+3TC+TDF(LP-80:once a week;3TC+TDF:once daily);

  • Lipovirtide 40mgDrug

    Lipovirtide 40mg+3TC+TDF(LP-80:once a week;3TC+TDF:once daily);

  • Lipovirtide 60mgDrug

    Lipovirtide 60mg+3TC+TDF(LP-80:once every 2 weeks;3TC+TDF:once daily);

  • DTGDrug

    DTG +3TC + TDF(once daily).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. HIV-1 RNA <50 copies/mlTime frame: at Day 169 after receiving Lipovirtide administration.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tianjin Second People's Hospital

    Tianjin, Tianjin Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.